8-K: Butterfly Network Appoints Caroll H. Neubauer to Board

Butterfly Network announced the appointment of Caroll H. Neubauer to its Board of Directors, effective May 18, 2026, strengthening its healthcare industry expertise.

Summary

• Butterfly Network, Inc. has appointed Caroll H. Neubauer to its Board of Directors, effective May 18, 2026.
• Mr. Neubauer will serve on the Board's Compensation Committee and Technology Committee.
• The Board size has been increased to eight directors.
• Dr. Erica Schwartz has notified the Board of her intention to resign as a director, contingent upon her confirmation as Director of the CDC.
• Mr. Neubauer brings extensive experience from B. Braun, where he helped grow annual revenue from approximately $1 billion to over $8 billion.
• He is a former Chairman and CEO of B. Braun USA and currently serves as an Executive Advisor to Water Street Healthcare Partners.
• Mr. Neubauer received the AdvaMed Lifetime Achievement Award in 2024 and served on the AdvaMed Board for over 15 years.
• He will receive standard compensation for non-employee directors, including a $300,000 grant of restricted stock units (RSUs) vesting over three years.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development due to the addition of a highly experienced director, though the contingent resignation of another director introduces a minor element of uncertainty.

Positives

• Appointment of Caroll H. Neubauer brings significant industry experience from a leading medical device company (B. Braun), where he was instrumental in growing revenue from $1 billion to over $8 billion.
• Mr. Neubauer's expertise in scaling businesses, navigating global markets, and complex regulatory environments is highly relevant to Butterfly's growth initiatives.
• His recognition with the AdvaMed Lifetime Achievement Award and extensive involvement in industry associations like AdvaMed highlight his leadership and influence.
• The appointment strengthens the Board's expertise in compensation and technology committees.
• Mr. Neubauer's positive outlook on Butterfly's financial momentum and strategic breadth is encouraging.
• The company is accelerating toward profitability while pursuing multiple growth initiatives.

Negatives

• Dr. Erica Schwartz's resignation is contingent on her confirmation as CDC Director, creating potential uncertainty regarding board composition until the confirmation process concludes.
• The timing and outcome of the CDC confirmation process for Dr. Schwartz are currently unknown.

Risks

• The timing and outcome of Dr. Erica Schwartz's confirmation process as Director of the CDC are uncertain and could impact the Board's composition.
• Potential challenges in scaling Butterfly's multi-faceted platform and achieving profitability while pursuing growth initiatives.

Future Outlook

Mr. Neubauer expressed optimism about Butterfly's financial momentum and strategic breadth, indicating a positive outlook for the company's growth initiatives and acceleration toward profitability.

Management Comments

• "Caroll spent three decades building and scaling one of the world's leading medical device companies, navigating global markets, complex regulatory environments, and large-scale commercial partnerships," said Joseph DeVivo, President, Chief Executive Officer and Chairman of Butterfly.
• "That breadth of experience - from growing a business across geographies to forging the kinds of industry relationships that open new markets - is directly relevant as Butterfly evolves into a multi-faceted platform. We are delighted to welcome him to the Board."
• "Butterfly has built a genuinely differentiated technology platform, and the company is at a compelling moment: accelerating toward profitability while pursuing multiple growth initiatives," said Mr. Neubauer.
• "That combination of financial momentum and strategic breadth is what makes this such an exciting time to join the Board. I look forward to working with Joe and the team to help Butterfly realize its full potential."

Industry Context

StockSavvy.ai notes that the appointment of Caroll H. Neubauer, a seasoned executive with a proven track record at B. Braun and significant industry recognition from AdvaMed, signals Butterfly Network's strategic focus on leveraging deep healthcare industry expertise to drive growth and navigate complex markets.

Comparison to Industry Standards

• Mr. Neubauer's experience at B. Braun, growing annual revenue from $1 billion to over $8 billion, exemplifies successful scaling within the medical device sector, a benchmark for many companies in the industry.
• His 15+ years on the AdvaMed Board and receipt of its Lifetime Achievement Award highlight leadership and influence comparable to other top executives in the advanced medical technology space.
• The standard compensation package for non-employee directors, including a $300,000 RSU grant vesting over three years, aligns with typical compensation structures for independent board members at publicly traded companies in the medtech sector.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Benefit from enhanced board expertise and strategic guidance, potentially leading to improved company performance and value.
• Employees: May see continued focus on growth and profitability initiatives, fostering a stable and dynamic work environment.
• Customers: Continued innovation and market expansion driven by experienced leadership could lead to improved product offerings and accessibility.

Next Steps

• Monitor the confirmation process for Dr. Erica Schwartz as Director of the CDC.
• Observe Mr. Caroll H. Neubauer's contributions to the Compensation and Technology Committees.
• Track Butterfly Network's progress towards profitability and growth initiatives.

Key Dates

Recommendation

The appointment of a highly experienced director is a positive step, but the contingent resignation of another director and the lack of new financial performance data mean the current outlook warrants a 'hold' recommendation pending further developments.

Keywords

Butterfly Network, Board of Directors, Caroll H. Neubauer, Director Appointment, Medical Device, Healthcare Industry, B. Braun, AdvaMed